Literature DB >> 10952960

Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: evidence from gene-knockout mice.

T Zhao1, L Xi, J Chelliah, J E Levasseur, R C Kukreja.   

Abstract

BACKGROUND: The mechanism of delayed preconditioning induced by activation of adenosine A(1) receptors (A(1)ARs) is not fully understood. We determined the role of inducible nitric oxide synthase (iNOS) in mediating adenosine-induced late cardioprotection using pharmacological inhibitors and iNOS gene-knockout mice. METHODS AND
RESULTS: Adult male mice were treated with saline or an A(1)AR agonist, 2-chloro-N(6)-cyclopentyladenosine (CCPA). Twenty-four hours later, the hearts were perfused in Langendorff mode and subjected to 30 minutes of global ischemia followed by 30 minutes of reperfusion. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX; 0.1 mg/kg IP) and S-methylisothiourea (SMT; 3 mg/kg IP) were used to block A(1)ARs and iNOS, respectively. Infarct size (IS) was measured by triphenyltetrazolium chloride staining, and iNOS expression was measured by Western blots. Myocardial IS was reduced from 24.0+/-3. 2% in the saline group to 12.2+/-2.5% in CCPA-treated mice (P<0.05). The infarct-reducing effect of CCPA was abrogated by DPCPX (29.3+/-3. 4%) and SMT (32.3+/-2.6%) and was absent in mice with targeted ablation of iNOS (23.9+/-1.6%). CCPA produced improvement in postischemic end-diastolic pressure, developed pressure, and rate-pressure product, which was also blocked by DPCPX and SMT. Increased iNOS protein expression observed in CCPA-treated hearts was diminished by DPCPX.
CONCLUSIONS: Selective activation of A(1)ARs produces delayed cardioprotection against ischemia/reperfusion injury in the mouse. Increased iNOS expression concomitant with the lack of protective effect of A(1)AR activation in iNOS gene-knockout mice suggests a direct cause-and-effect relationship of iNOS in adenosine-induced late cardioprotection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952960     DOI: 10.1161/01.cir.102.8.902

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels.

Authors:  Janet R Manning; Gregory Carpenter; Darius R Porter; Stacey L House; Daniel A Pietras; Thomas Doetschman; Jo el J Schultz
Journal:  Growth Factors       Date:  2012-02-06       Impact factor: 2.511

2.  Activation of hypoxia-inducible factor-1 ameliorates postischemic renal injury via inducible nitric oxide synthase.

Authors:  Xiao-Li Zhang; Zhen-Wen Yan; Wei-Wen Sheng; Jing Xiao; Zhen-Xing Zhang; Zhi-Bin Ye
Journal:  Mol Cell Biochem       Date:  2011-07-14       Impact factor: 3.396

3.  Inducible nitric oxide synthase promoter polymorphism affords protection against cognitive dysfunction after carotid endarterectomy.

Authors:  Gene T Yocum; John G Gaudet; Susie S Lee; Yaakov Stern; Lauren A Teverbaugh; Robert R Sciacca; Charles W Emala; Donald O Quest; Paul C McCormick; James F McKinsey; Nicholas J Morrissey; Robert A Solomon; E Sander Connolly; Eric J Heyer
Journal:  Stroke       Date:  2009-03-12       Impact factor: 7.914

4.  Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70.

Authors:  Huei-Wen Chen; Chiang-Ting Chien; Sung-Liang Yu; Yuan-Teh Lee; Wen-Jone Chen
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS.

Authors:  Yiru Guo; Adam B Stein; Wen-Jian Wu; Xiaoping Zhu; Wei Tan; Qianhong Li; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-08       Impact factor: 4.733

6.  Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism.

Authors:  Qianhong Li; Yiru Guo; Yu-Ting Xuan; Charles J Lowenstein; Susan C Stevenson; Sumanth D Prabhu; Wen-Jian Wu; Yanqing Zhu; Roberto Bolli
Journal:  Circ Res       Date:  2003-04-18       Impact factor: 17.367

7.  Ischemic and pharmacological preconditioning induces further delayed protection in transgenic mouse cardiac myocytes over-expressing adenosine A1 receptors (A1AR): role of A1AR, iNOS and K(ATP) channels.

Authors:  Mohammed A Nayeem; G Paul Matherne; S Jamal Mustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-25       Impact factor: 3.000

8.  Adenosine A1-Receptors Modulate mTOR Signaling to Regulate White Matter Inflammatory Lesions Induced by Chronic Cerebral Hypoperfusion.

Authors:  Pengfei Cheng; Xuzheng Zuo; Yifei Ren; Shunjie Bai; Weiju Tang; Xiuying Chen; Gong Wang; Haoxiang Wang; Wen Huang; Peng Xie
Journal:  Neurochem Res       Date:  2016-09-23       Impact factor: 3.996

9.  Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms.

Authors:  Ian Moench; Howard Prentice; Zach Rickaway; Herbert Weissbach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

10.  Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse.

Authors:  Fadi N Salloum; Anindita Das; Christopher S Thomas; Chang Yin; Rakesh C Kukreja
Journal:  J Mol Cell Cardiol       Date:  2007-08-30       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.